EE307 Cost-Utility Analysis of Pegunigalsidase Alfa Compared to Agalsidase Alfa and Agalsidase Beta for the Treatment of Adult Patients With Fabry Disease in Greece
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.691
https://www.valueinhealthjournal.com/article/S1098-3015(25)03248-6/fulltext
Title :
EE307 Cost-Utility Analysis of Pegunigalsidase Alfa Compared to Agalsidase Alfa and Agalsidase Beta for the Treatment of Adult Patients With Fabry Disease in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)03248-6&doi=10.1016/j.jval.2025.09.691
First page :
Section Title :
Open access? :
No
Section Order :
10269